NCT07214987View on ClinicalTrials.gov

PDT For Induction Therapy For Head And Neck Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 9, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

September 1, 2029

Conditions
Squamous Cell CarcinomaHead and Neck Cancer Squamous Cell CarcinomaHead and Neck Cancer
Interventions
DRUG

Toripalimab-tpzi

Toripalimab-tpzi is a humanized IgG4 monoclonal antibody specific against human PD-1.

DRUG

Cisplatin

Cisplatin is an injectable chemotherapy agent classified as a platinum-based alkylating agent.

DRUG

Docetaxel

Docetaxel is a taxane chemotherapy agent.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Coherus Oncology, Inc.
All Listed Sponsors
collaborator

Coherus Oncology, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER